Table 1.
Sociodemographic and Clinical Characteristics of Participants at Baseline
| Variables | N | Results |
|---|---|---|
| Age (years old) | 60.07 ± 12.10 | |
| Weight (kg) | 68.37 ± 13.63 | |
| Height (m) | 1.59 ± 0.08 | |
| BMI (kg/m2) | 26.79 ± 5.33 | |
| Sex (%) | ||
| M | 14 | 36.84 |
| F | 24 | 63.16 |
| Cancer diagnostic (months) | 22.37 ± 23.62 | |
| Cancer diagnostic sites (%) | ||
| Gastrointestinal tract | 6 | 15.79 |
| Breast | 13 | 34.21 |
| Abdominal and pelvic | 10 | 26.31 |
| Oropharyngeal | 4 | 10.53 |
| Others | 5 | 13.16 |
| Stage (%) | ||
| 0 | 2 | 5.26 |
| I | 11 | 28.94 |
| II | 16 | 42.11 |
| III | 9 | 23.69 |
| IV | — | — |
| Chemotherapeutic drugs (%) | ||
| Taxanes | 13 | 34.21 |
| Platinum | 7 | 18.42 |
| Alkaloids | 7 | 18.42 |
| Others | 11 | 28.95 |
| Types of treatments (cycles) | 10.32 ± 9.41 | |
| Chemotherapy sessions | ||
| EXE protocol | 2.72 ± 0.46 | |
| Session (times per week) | 109.36 ± 21.23 | |
BMI; Other (Leukemia, lymphoma, bone cancer, brain cancer, lymphoma chronic myelogenous); other medications: CMF, carboplatin–methotrexate–fluorouracil; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; kg: kilogram; m: meter; kg/m2: kilogram per square meter; n = sample number; %: percentage.
BMI, body mass index.